|Articles|September 12, 2017

Poll: Were you warned about side effects?

Author(s)Staff

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

It’s Okay Not To Be Okay Through a Cancer Diagnosis

ByLinda Cohen

December 5th 2025

Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center discussed basics of gastrointestinal stromal tumors.

Essential Insights on GIST and Gleevec for Patients

ByDr. Ajay Gupta

December 5th 2025

TARA-002 Shows Potential in BCG-Naive NMIBC Treatment

ByRyan Scott

December 5th 2025

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of.

What Patients With AML Need to Know About Azacitidine and Venclexta

ByDr. Daniel Peters

December 5th 2025

$The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy: © stock.adobe.com.$

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

ByAlex Biese

December 4th 2025

Poll: Were you warned about side effects?

Newsletter

Related Content

It’s Okay Not To Be Okay Through a Cancer Diagnosis

Essential Insights on GIST and Gleevec for Patients

TARA-002 Shows Potential in BCG-Naive NMIBC Treatment

What Patients With AML Need to Know About Azacitidine and Venclexta

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

Trending on CURE

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection

What Patients Should Know About EGFR Mutated Lung Cancer Treatment

Every FDA Oncology Approval From November 2025

Chemo Side Effects for Breast Cancer Led to Weeks in the Hospital